肝巨噬细胞极化对肝硬化发生的影响及临床应用研究进展*

doi:10.3969/j.issn.1672-5069.2023.01.039

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (1): 149-152.doi: 10.3969/j.issn.1672-5069.2023.01.039

• 综述 • 上一篇

肝巨噬细胞极化对肝硬化发生的影响及临床应用研究进展^*

吴笛综述, 罗业浩, 黄安审校

530000 南宁市广西中医药大学

收稿日期:2021-12-23 出版日期:2023-01-10 发布日期:2023-02-07
通讯作者: 黄安,E-mail:2955339849@qq.com
作者简介:吴笛,女,24岁,硕士研究生。研究方向:民族医学方药和技法研究。E-mail:1778281294@qq.com
基金资助:
^*广西壮族自治区医学高层次骨干人才培养‘139'计划资助项目[编号:桂卫科教发〔2020〕15号];广西壮族自治区卫生健康委员会壮医应用基础研究重点实验室项目[编号:桂卫科教发〔2020〕17号];广西中医药大学“岐黄工程”高层次人才团队培育项目(编号:2021003);中医学广西一流学科建设项目[编号:桂教科研〔2018〕12号];广西中医药大学A类“桂派中医药传承创新团队”:壮医毒病临床医学研究与应用创新团队(编号:2022A003);广西中医药大学桂派杏林青年英才(编号:2022035)

Impact of hepatic macrophages polarization on pathogenesis of liver cirrhosis

Wu Di, Luo Yehao, Huang An

Guangxi University of Traditional Chinese Medicine, Nanning 530000, Guangxi Zhuang Autonomous Region, China

Received:2021-12-23 Online:2023-01-10 Published:2023-02-07

摘要/Abstract

摘要： 肝硬化是由一种或多种病理性因素长期反复作用于机体而造成的非常严重的慢性进行性肝脏疾病,而肝巨噬细胞被认为是肝脏损伤和修复的重要介质。本文综述了不同表型的肝巨噬细胞在肝硬化发生发展过程中的作用,叙述了肝巨噬细胞极化对肝脏疾病的重要影响。

关键词: 肝硬化, 肝巨噬细胞, 肝纤维化

Abstract: Liver cirrhosis is a very serious chronic progressive liver disease caused by one or more pathological factors repeatedly. The hepatic macrophages is regarded as the important cells for liver damage and repair. The different phenotypic liver macrophages on inflammation of liver are discussed, and the liver macrophage polarization is emphasized in this paper.

Key words: Liver cirrhosis, Macrophages, Liver fibrosis

吴笛, 罗业浩, 黄安. 肝巨噬细胞极化对肝硬化发生的影响及临床应用研究进展^*[J]. 实用肝脏病杂志, 2023, 26(1): 149-152.

Wu Di, Luo Yehao, Huang An. Impact of hepatic macrophages polarization on pathogenesis of liver cirrhosis[J]. Journal of Practical Hepatology, 2023, 26(1): 149-152.

参考文献

[1] GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet,2020,5(3):245-266.
[2] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol, 2019,70(1):151-171.
[3] Palmer LB, Kuftinec G, Pearlman M, et al. Nutrition in cirrhosis.Curr Gastroenterol Rep, 2019,21(8):38.
[4] Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol, 2020,15:123-147.
[5] Van der Heide D, Weiskirchen R, Bansal R. Therapeutic targeting of hepatic macrophages for the treatment of liver diseases. Front Immunol, 2019,10:2852.
[6] Shan Z, Ju C. Hepatic macrophages in liver injury. Front Immunol,2020,11:322.
[7] Uderhardt S, Martins AJ, Tsang JS, et al. Resident macrophages cloak tissue microlesions to prevent neutrophil-driven inflammatory damage. Cell,2019,177(3):541-555,e617.
[8] Horst AK, Tiegs G, Diehl L. Contribution of macrophage efferocytosis to liver homeostasis and disease. Front Immunol,2019,10:2670.
[9] Elchaninov AV, Fatkhudinov TK, Vishnyakova PA, et al. Phenotypical and functional polymorphism of liver resident macrophages. Cells,2019,8(9):1032.
[10] Wen Y, Lambrecht J, Ju C, et al. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol, 2021,18(1):45-56.
[11] Muntjewerff EM, Meesters LD, van den Bogaart G. Antigen cross-presentation by macrophages. Front Immunol,2020,11:1276.
[12] Dou L, Shi X, He X, et al. Macrophage phenotype and function in liver disorder. Front Immunol,2020,10:3112.
[13] Geervliet E, Bansal R. Matrix metalloproteinases as potential biomarkers and therapeutic targets in liver diseases. Cells,2020,9(5):1212.
[14] Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol,2021,18(3):151-166.
[15] Gao B, Ahmad MF, Nagy LE, et al. Inflammatory pathways in alcoholic steatohepatitis. J Hepatol,2019,70(2):249-259.
[16] Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci,2019,20(23):6008.
[17] Zhou R, Fan X, Schnabl B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Transl Res,2019,209:22-38.
[18] Fukui H. Leaky gut and gut-liver axis in liver cirrhosis: clinical studies update. Gut Liver,2021,15(5):666-676.
[19] Meyer F, Bannert K, Wiese M, et al. Molecular mechanism contributing to malnutrition and sarcopenia in patients with liver cirrhosis. Int J Mol Sci,2020,21(15):5357.
[20] Shrivastava R, Shukla N. Attributes of alternatively activated (M2) macrophages. Life Sci,2019,224:222-231.
[21] Luque-Campos N, Bustamante-Barrientos FA, Pradenas C, et al. The macrophage response is driven by mesenchymal stem cell-mediated metabolic reprogramming. Front Immunol,2021,12:624746.
[22] Gan J, Liu C, Li H, et al. Accelerated wound healing in diabetes by reprogramming the macrophages with particle-induced clustering of the mannose receptors. Biomaterials,2019,219:119340.
[23] Wang LX, Zhang SX, Wu HJ, et al. M2b macrophage polarization and its roles in diseases. J Leukoc Biol,2019,106(2):345-358.
[24] Ye L, He S, Mao X,et al. Effect of hepatic macrophage polarization and apoptosis on liver ischemia and reperfusion injury during liver transplantation. Front Immunol,2020,11:1193.
[25] Orecchioni M, Ghosheh Y, Pramod AB, et al. Macrophage polarization: different gene signatures in M1(LPS⁺) vs. classically and M2(LPS^-) vs. alternatively activated macrophages. Front Immunol, 2019,10:1084.
[26] Cheng D, Chai J, Wang H, et al. Hepatic macrophages: key players in the development and progression of liver fibrosis. Liver Int,2021,41(10):2279-2294.
[27] Sumitomo R, Hirai T, Fujita M, et al. M2 tumor-associated macrophages promote tumor progression in non-small-cell lung cancer. Exp Ther Med, 2019,18(6):4490-4498.
[28] Yahaya MAF, Lila MAM, Ismail S, et al. Tumour-associated macrophages (TAMs) in colon cancer and how to reeducate them. J Immunol Res,2019,2019:2368249.
[29] Cao L, Che X, Qiu X, et al. M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer. Cancer Manag Res,2019,11:6125-6138.
[30] Colino CI, Lanao JM, Gutierrez-Millan C. Targeting of hepatic macrophages by therapeutic nanoparticles. Front Immunol,2020,11:218.
[31] Lee CH, Chun T. Anti-inflammatory role of TAM family of receptor tyrosine kinases via modulating macrophage function. Mol Cells,2019,42(1):1-7.
[32] Chang Y, Li H. Hepatic antifibrotic pharmacotherapy: as we approaching success? J Clin Transl Hepatol,2020,8(2):222-229.
[33] Wu BM, Liu JD, Li YH, et al. Margatoxin mitigates CCl₄induced hepatic fibrosis in mice via macrophage polarization, cytokine secretion and STAT signaling. Int J Mol Med,2020,45(1):103-114.
[34] Ahn SB, Jun DW, Kang BK, et al. Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Sci Rep,2019,9(1):5688.
[35] Lee NY, Suk KT. The role of the gut microbiome in liver cirrhosis treatment. Int J Mol Sci,2020,22(1):199.
[36] Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and Its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci,2019,20(2):395.
[37] Ambade A, Lowe P, Kodys K, et al. Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice. Hepatology,2019,69(3):1105-1121.
[38] Hintermann E, Christen U. The many roles of cell adhesion molecules in hepatic fibrosis. Cells,2019,8(12):1503.
[39] Piersma B, Bank RA. Collagen cross-linking mediated by lysyl hydroxylase 2: an enzymatic battlefield to combat fibrosis. Essays Biochem,2019,63(3):377-387.
[40] Zhou GP, Jiang YZ, Sun LY, et al. Therapeutic effect and safety of stem cell therapy for chronic liver disease: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther, 2020,11(1):419.
[41] Kweon M, Kim JY, Jun JH, et al. Research trends in the efficacy of stem cell therapy for hepatic diseases based on microRNA profiling. Int J Mol Sci, 2020,22(1):239.
[42] Moon SH, Lee CM, Park SH, et al. Effects of hepatocyte growth factor gene-transfected mesenchymal stem cells on dimethylnitrosamine-induced liver fibrosis in rats. Growth Factors, 2019,37(3-4):105-119.

肝巨噬细胞极化对肝硬化发生的影响及临床应用研究进展^*

Impact of hepatic macrophages polarization on pathogenesis of liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李蕊, 秦秋实, 张玥, 曹颖, 闫杰, 朱鏐娈. E型前列腺素受体4对CCL₄诱导的肝损伤小鼠肝组织肝纤维化相关蛋白表达的影响^*[J]. 实用肝脏病杂志, 2023, 26(1): 15-18.
[2]	王燕, 李伟甲, 李娅, 陈香宇, 徐峰. CCl₄诱导的肝纤维化小鼠和HSC-T6细胞miR-122水平变化及其意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(1): 19-22.
[3]	徐海波, 苏惠婷, 熊异平, 徐远久, 邓强. 乙型肝炎肝硬化患者外周血dNLR、MLR和SII变化及其临床意义分析^*[J]. 实用肝脏病杂志, 2023, 26(1): 71-74.
[4]	李苏苏, 董媛, 贾浩延, 秦颖. 门冬氨酸鸟氨酸联合结肠透析治疗肝性脑病患者疗效及其对血浆β-EP和LPS的影响^*[J]. 实用肝脏病杂志, 2023, 26(1): 75-78.
[5]	陈晔, 陈晓岚, 曹丽玲, 刘昌华. 接受TIPS治疗的肝硬化患者术后心脏结构与功能指标的变化评价^*[J]. 实用肝脏病杂志, 2023, 26(1): 79-82.
[6]	刘南南, 李卫, 赵守松. 简化版动物命名试验对肝硬化并发轻微性肝性脑病的诊断价值及相关因素分析^*[J]. 实用肝脏病杂志, 2023, 26(1): 83-86.
[7]	戴欢, 李凯, 朱永湘, 王超. 内镜下套扎和注射硬化剂治疗乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 87-90.
[8]	许青, 杨健, 宗金娟. 特发性非肝硬化门静脉高压症患者肝脏影像学和病理学特征分析^*[J]. 实用肝脏病杂志, 2023, 26(1): 91-94.
[9]	韩涛, 刘艳迪, 胡家轩. 肝病合并肾损伤临床诊治新进展[J]. 实用肝脏病杂志, 2022, 25(6): 761-763.
[10]	蒋莹莹, 丁惠国. 肝硬化并发急性肾损伤临床管理现状与挑战[J]. 实用肝脏病杂志, 2022, 25(6): 764-767.
[11]	韩芳, 李佳峥, 南月敏. 肝硬化并发急性肾损伤诊治进展[J]. 实用肝脏病杂志, 2022, 25(6): 768-771.
[12]	王晓华, 曾雅琳, 郭萃蓉. 非酒精性脂肪性肝病进展性肝纤维化患者空腹血糖受损和胰岛素抵抗调查^*[J]. 实用肝脏病杂志, 2022, 25(6): 812-815.
[13]	沈亦亮, 沈冬元, 陈永莹, 江凯, 朱逸明, 葛尚. 肝硬化患者肝内LR-3类结节恶变风险评估及预测模型的建立^*[J]. 实用肝脏病杂志, 2022, 25(6): 836-839.
[14]	徐超, 李兰, 罗东, 赵海云, 彭飞. TIPS术治疗的肝硬化并发EVB患者医院内死亡风险预测模型的构建与应用^*[J]. 实用肝脏病杂志, 2022, 25(6): 840-843.
[15]	林秀慧, 李南, 张娇珍, 符庆忠, 林秀华. 慢性HBV感染者外周血PNPLA3/PRKAA1基因多态性与肝硬化发生关系研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 844-847.